Double-blind cross-over trial comparing intranasal beclomethasone dipropionate and placebo in perennial rhinitis.
Twenty-five patients with perennial rhinitis completed a double-blind cross-over trial of intranasal beclomethasone dipropionate 200 mug daily and placebo. Of these patients 19 preferred the active drug and two preferred placebo. There were significant reductions in symptom scores for nasal obstruction and rhinorrhoea and in the use of decongestant nasal drops when using the active drug. No changes in morning plasma cortisol levels occurred during the three-week treatment period.
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001507:Beclomethasone / Q000008:administration & dosage* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008875:Middle Aged; D014663:Nasal Decongestants / Q000627:therapeutic use; D010919:Placebos; D012220:Rhinitis / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D006634:Histamine H1 Antagonists; D014663:Nasal Decongestants; D010919:Placebos; D001507:Beclomethasone; D006854:Hydrocortisone